Treatment of OSA using mandibular advancement versus CPAP in improving cardiovascular health.
Yi-Hui Ou, Juliana Tereza Colpani, Crystal S Cheong et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial compared the effectiveness of mandibular advancement devices (MAD) and continuous positive airway pressure (CPAP) in reducing 24-hour ambulatory blood pressure in 220 participants with moderate-to-severe obstructive sleep apnea over 12 months. The study found that MAD is non-inferior to CPAP, with a mean arterial blood pressure reduction of 2.3 mmHg in the MAD group versus 1.0 mmHg in the CPAP group.
Key findings
- MAD reduced 24-hour mean arterial BP by 2.3 mmHg compared to baseline.
- CPAP reduced 24-hour mean arterial BP by 1.0 mmHg compared to baseline.
- Excessive daytime sleepiness prevalence decreased from 30.3% to 10.1% in the MAD group.
- Excessive daytime sleepiness prevalence decreased from 38.5% to 7.7% in the CPAP group.
Why it matters
Understanding the comparative effectiveness of MAD and CPAP in managing obstructive sleep apnea can guide clinicians in selecting appropriate treatment options for patients with hypertension and cardiovascular risk, potentially improving patient adherence and outcomes.